TN2018000118A1 - 1,3,4-thiadiazole compounds and their use in treating cancer - Google Patents
1,3,4-thiadiazole compounds and their use in treating cancerInfo
- Publication number
- TN2018000118A1 TN2018000118A1 TNP/2018/000118A TN2018000118A TN2018000118A1 TN 2018000118 A1 TN2018000118 A1 TN 2018000118A1 TN 2018000118 A TN2018000118 A TN 2018000118A TN 2018000118 A1 TN2018000118 A1 TN 2018000118A1
- Authority
- TN
- Tunisia
- Prior art keywords
- sup
- sub
- treating cancer
- thiadiazole compounds
- compound
- Prior art date
Links
- 150000004869 1,3,4-thiadiazoles Chemical class 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 101100176011 Caenorhabditis elegans gls-1 gene Proteins 0.000 abstract 1
- 102000009127 Glutaminase Human genes 0.000 abstract 1
- 108010073324 Glutaminase Proteins 0.000 abstract 1
- -1 e.g. Proteins 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562260784P | 2015-11-30 | 2015-11-30 | |
| PCT/EP2016/079253 WO2017093301A1 (en) | 2015-11-30 | 2016-11-30 | 1,3,4-thiadiazole compounds and their use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2018000118A1 true TN2018000118A1 (en) | 2019-10-04 |
Family
ID=57460503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP/2018/000118A TN2018000118A1 (en) | 2015-11-30 | 2016-11-30 | 1,3,4-thiadiazole compounds and their use in treating cancer |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US10040789B2 (enExample) |
| EP (1) | EP3383872B1 (enExample) |
| JP (1) | JP6821680B2 (enExample) |
| KR (1) | KR20180083411A (enExample) |
| CN (1) | CN108349965B (enExample) |
| AR (1) | AR106875A1 (enExample) |
| AU (1) | AU2016361834B2 (enExample) |
| BR (1) | BR112018008330B1 (enExample) |
| CA (1) | CA3005517C (enExample) |
| CL (1) | CL2018001409A1 (enExample) |
| CO (1) | CO2018006930A2 (enExample) |
| DK (1) | DK3383872T3 (enExample) |
| DO (1) | DOP2018000135A (enExample) |
| EA (1) | EA035519B9 (enExample) |
| ES (1) | ES2796562T3 (enExample) |
| IL (1) | IL259508A (enExample) |
| MX (1) | MX2018006483A (enExample) |
| MY (1) | MY195680A (enExample) |
| NI (1) | NI201800063A (enExample) |
| NZ (1) | NZ743699A (enExample) |
| PE (1) | PE20181522A1 (enExample) |
| PH (1) | PH12018501133A1 (enExample) |
| SG (1) | SG11201803808VA (enExample) |
| SV (1) | SV2018005700A (enExample) |
| TN (1) | TN2018000118A1 (enExample) |
| TW (1) | TW201731511A (enExample) |
| WO (1) | WO2017093301A1 (enExample) |
| ZA (1) | ZA201804361B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201520959D0 (en) | 2015-11-27 | 2016-01-13 | Astrazeneca Ab And Cancer Res Technology Ltd | Bis-pyridazine compounds and their use in treating cancer |
| US9938265B2 (en) | 2015-11-30 | 2018-04-10 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| US10323028B2 (en) | 2015-11-30 | 2019-06-18 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| ES2939506T3 (es) | 2018-10-16 | 2023-04-24 | Medshine Discovery Inc | Derivado de tiadiazol y usos del mismo como inhibidor de GLS1 para el tratamiento de cáncer |
| CN114560855B (zh) * | 2021-03-26 | 2023-05-23 | 成都苑东生物制药股份有限公司 | 环烷基甲酰胺类衍生物、其制备方法及用途 |
| WO2025196447A1 (en) | 2024-03-22 | 2025-09-25 | Sitryx Therapeutics Limited | Thiadiazoles as glutaminase 1 inhibitors |
| WO2025196446A1 (en) | 2024-03-22 | 2025-09-25 | Sitryx Therapeutics Limited | Thiadiazoles as glutaminase 1 inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108785305B (zh) * | 2011-11-21 | 2021-10-29 | 卡利泰拉生物科技公司 | 谷氨酰胺酶的杂环抑制剂 |
| WO2014079011A1 (en) | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
| KR20160100407A (ko) | 2014-01-06 | 2016-08-23 | 리젠 파마슈티컬스 소시에떼 아노님 | 신규한 글루타미나제의 저해제 |
| GB201409624D0 (en) * | 2014-05-30 | 2014-07-16 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| US9938265B2 (en) * | 2015-11-30 | 2018-04-10 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| US10323028B2 (en) * | 2015-11-30 | 2019-06-18 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
-
2016
- 2016-11-29 TW TW105139334A patent/TW201731511A/zh unknown
- 2016-11-29 US US15/362,989 patent/US10040789B2/en active Active
- 2016-11-30 SG SG11201803808VA patent/SG11201803808VA/en unknown
- 2016-11-30 KR KR1020187017163A patent/KR20180083411A/ko not_active Withdrawn
- 2016-11-30 TN TNP/2018/000118A patent/TN2018000118A1/en unknown
- 2016-11-30 AR ARP160103664A patent/AR106875A1/es unknown
- 2016-11-30 MY MYPI2018702070A patent/MY195680A/en unknown
- 2016-11-30 EP EP16805078.9A patent/EP3383872B1/en active Active
- 2016-11-30 ES ES16805078T patent/ES2796562T3/es active Active
- 2016-11-30 WO PCT/EP2016/079253 patent/WO2017093301A1/en not_active Ceased
- 2016-11-30 NZ NZ743699A patent/NZ743699A/en unknown
- 2016-11-30 BR BR112018008330-5A patent/BR112018008330B1/pt active IP Right Grant
- 2016-11-30 PE PE2018001012A patent/PE20181522A1/es unknown
- 2016-11-30 DK DK16805078.9T patent/DK3383872T3/da active
- 2016-11-30 JP JP2018527201A patent/JP6821680B2/ja active Active
- 2016-11-30 EA EA201891239A patent/EA035519B9/ru not_active IP Right Cessation
- 2016-11-30 MX MX2018006483A patent/MX2018006483A/es unknown
- 2016-11-30 CN CN201680067210.XA patent/CN108349965B/zh active Active
- 2016-11-30 CA CA3005517A patent/CA3005517C/en active Active
- 2016-11-30 AU AU2016361834A patent/AU2016361834B2/en active Active
-
2018
- 2018-05-22 IL IL259508A patent/IL259508A/en active IP Right Grant
- 2018-05-24 CL CL2018001409A patent/CL2018001409A1/es unknown
- 2018-05-29 DO DO2018000135A patent/DOP2018000135A/es unknown
- 2018-05-29 NI NI201800063A patent/NI201800063A/es unknown
- 2018-05-29 PH PH12018501133A patent/PH12018501133A1/en unknown
- 2018-05-29 SV SV2018005700A patent/SV2018005700A/es unknown
- 2018-06-28 ZA ZA2018/04361A patent/ZA201804361B/en unknown
- 2018-06-29 CO CONC2018/0006930A patent/CO2018006930A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018501133A1 (en) | 1,3,4-thiadiazole compounds and their use in treating cancer | |
| MX2021003843A (es) | Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer. | |
| GEP20217248B (en) | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh | |
| PH12018501073A1 (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| MX2017008417A (es) | Procedimientos para preparar inhibidores de cinasa 1 reguladora de señal de apoptosis (ask1). | |
| MX392829B (es) | Analogos sinteticos de las ecteinascidinas y su uso como agentes antitumorales | |
| MX2017013880A (es) | Derivados del acido tetrahidronaftiridinil propionico y usos de los mismos. | |
| SG11201900868XA (en) | Ido1 inhibitor and preparation method and application thereof | |
| PH12016502394A1 (en) | 1, 3, 4-thiadiazole compounds and their use in treating cancer | |
| PH12018501131A1 (en) | 1,3,4-thiadiazole compounds and their use in treating cancer | |
| MX388612B (es) | Intermediarios para preparar herbicidas de piridazinona y proceso para prepararlos. | |
| PH12016502130B1 (en) | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect | |
| PH12018501132A1 (en) | 1,3,4-thiadiazole compounds and their use in treating cancer | |
| NZ764463A (en) | Heterocyclic compound and application thereof in medicine | |
| MY199733A (en) | New use of n,n-bis-2-mercaptoethyl isophthalamide | |
| PH12022551548A1 (en) | Substituted hydroxystilbene compounds and derivatives synthesis and uses thereof | |
| MX395659B (es) | Compuestos triciclicos y su uso en el tratamiento del cancer | |
| PH12020551919A1 (en) | 4-amino-6-(1,3-benzodioxole)picolinates and their use as herbicides. | |
| PL3898612T3 (pl) | Podstawione pirydynyloksybenzeny, ich sole oraz zastosowanie jako aktywne składniki herbicydowe |